Kopran’s arm purchases API facility at Gujarat

15 May 2018 Evaluate

Kopran’s wholly owned subsidiary - Kopran Research Laboratories has purchased Maxheal Pharmaceuticals (India), an API facility at Panoli in the state of Gujarat on Slump Sale basis.

The acquired unit will be suitably upgraded and expanded. The expansion of the unit is expected to be completed by December, 2018 to launch new line of products.

Kopran is engaged in pharmaceutical business. The company’s business units include Finished Dosage Forms, Active Pharmaceutical Ingredients, Research and Development, and Consumer Healthcare.


Kopran Share Price

194.35 -1.85 (-0.94%)
30-Apr-2025 11:14 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1831.45
Dr. Reddys Lab 1190.95
Cipla 1562.50
Lupin 2114.50
Zydus Lifesciences 898.05
View more..
© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.
×
Please wait your portfolio is updating...